Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11596696 Combination therapy with an anti-CD25 antibody-drug conjugate

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

March 7, 2023

0

Patent Application Number

166057080

Date Filed

April 20, 2018

0

Patent Citations

US Patent 10081681 Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors

US Patent 10259882 Anti-OX40 antibodies

0

US Patent 10479838 Antibodies to CD40 with enhanced agonist activity

US Patent 10544225 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

US Patent 10690674 Anti-GITR antibodies for cancer diagnostics

US Patent 10695433 Pyrrolobenzodiazepine-antibody conjugates

0

US Patent 10736903 Pyrrolobenzodiazepine-anti-PSMA antibody conjugates

US Patent 10751346 Pyrrolobenzodiazepine—anti-PSMA antibody conjugates

...

Patent Citations Received

US Patent 11779650 Pyrrolobenzodiazepine-antibody conjugates

Patent Primary Examiner

Karl J Puttlitz

0

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11596696 Combination therapy with an anti-CD25 antibody-drug conjugate

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool